Literature DB >> 14672612

A randomized placebo controlled trial of vitamin E for alcoholic hepatitis.

Esteban Mezey1, James J Potter, Lynda Rennie-Tankersley, Juan Caballeria, Albert Pares.   

Abstract

BACKGROUND/AIMS: The effect of vitamin E administration on clinical and laboratory parameters of liver function and on markers of fibrogenesis was assessed in patients with mild to moderate alcoholic hepatitis in a double blind placebo controlled randomized trial.
METHODS: Twenty-five patients received 1000 I.U. of vitamin E per day, while 26 patients received placebo for 3 months. The patients were followed for 1 year after entry into the trial.
RESULTS: Vitamin E did not result in significant greater decreases in serum aminotransferases and serum bilirubin or in greater increases in serum albumin as compared with placebo. Prothrombin time did not change, while serum creatinine remained in the normal range. Monocyte nuclear nuclear factor-kappa B binding activity decreased in patients who remained abstinent, regardless of whether they received vitamin E. As regards markers of hepatic fibrogenesis, vitamin E treatment decreased serum hyaluronic acid (P<0.05) while serum aminoterminal peptide of type III procollagen did not change in either group. Four patients in the treatment group and five in the placebo group died during the 1-year study.
CONCLUSIONS: Vitamin E treatment improves serum hyaluronic acid but has no beneficial effects on tests of liver function in patients with mild to moderate alcoholic hepatitis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14672612     DOI: 10.1016/s0168-8278(03)00476-8

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  56 in total

Review 1.  Hepatic stellate cells and innate immunity in alcoholic liver disease.

Authors:  Yang-Gun Suh; Won-Il Jeong
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

2.  Proteasome inhibitor treatment in alcoholic liver disease.

Authors:  Fawzia Bardag-Gorce
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

3.  Recent and currently emerging medical treatment options for the treatment of alcoholic hepatitis.

Authors:  Gabriel L Reep; Roger D Soloway
Journal:  World J Hepatol       Date:  2011-08-27

4.  Hepatobiliary Quiz (Answers)-15 (2015).

Authors:  Sahaj Rathi; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2015-10-27

Review 5.  Clinical implications of oxidative stress and antioxidant therapy.

Authors:  Gerald W Dryden; Ion Deaciuc; Gavin Arteel; Craig J McClain
Journal:  Curr Gastroenterol Rep       Date:  2005-08

Review 6.  Reprint of: Nutrition in the Management of Cirrhosis and its Neurological Complications.

Authors:  Chantal Bémeur; Roger F Butterworth
Journal:  J Clin Exp Hepatol       Date:  2015-02-19

Review 7.  Pathophysiological basis for antioxidant therapy in chronic liver disease.

Authors:  Jesús Medina; Ricardo Moreno-Otero
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 8.  Use of mesenchymal stem cells to treat liver fibrosis: current situation and future prospects.

Authors:  Silvia Berardis; Prenali Dwisthi Sattwika; Mustapha Najimi; Etienne Marc Sokal
Journal:  World J Gastroenterol       Date:  2015-01-21       Impact factor: 5.742

9.  Hepatobiliary quiz 11 (2014).

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2014-09

10.  Current Management and Future Treatment of Alcoholic Hepatitis.

Authors:  Mack C Mitchell; Thomas Kerr; H Franklin Herlong
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.